Search
for
Sort by
Research 31–60 of 1000+
- ASSESSING THE EFFECTIVENESS AND SAFETY OF LOW-DOSE ORAL MINOXIDIL IN ANDROGENETIC ALOPECIA: A 24-WEEK CLINICAL STUDY
- 1396 Interferon-24 regulates the expression of MMP1 and dermal collagen of the skin
- P111 : Low-Level light therapy in the treatment of androgenetic alopecia: A 24-week, randomized, double-blind, sham device-controlled multicenter trial
- A combination of pyridine‐2, 4‐dicarboxylic acid diethyl ester and resveratrol stabilizes hypoxia‐inducible factor 1‐alpha and improves hair density in female volunteers
- The Beneficial Effects of an Oriental Herbal Complex Supplement on Women’s Hair and Scalp Conditions: A 24-week, Randomized, Double-blind, Placebo-controlled Study
- Experimental Evaluation of 3-meta-Pyridine-1,2,4-Oxadiazole Derivative of Deoxycholic Acid as a Prototype of 5-α-Reductase Inhibitors in In Silico and In Vivo Models
- Experimental Assessment of 3-<i>meta</i>-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors <i>in silico</i> and <i>in vivo</i> Models
- Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil
- Characteristics of Hypertrichosis Induced by 24-week Low-dose (5 mg Daily) Oral Minoxidil in Male Pattern Hair Loss Treatment
- Normoglycemia and type 2 diabetes: exploring secreted frizzled-4, insulin resistance, and waist-height ratio
- Multiple endocrine defects in adult-onset Sprouty1/2/4 triple knockout mice
- Bone morphogenetic proteins 4 and 2/7 induce osteogenic differentiation of mouse skin derived fibroblast and dermal papilla cells
- Rational Design and Synthesis of 4-((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
- Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues
- Areata progressing to totalis: A 24-month journey of hair regrowth at Dr. Batra’s
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1<i>H</i>-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
- Synthesis, Crystal Structure and Supramolecular Features of Novel 2,4-Diaminopyrimidine Salts
- Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Immunological characteristics and histological distribution of human hair fibrous proteins studied with anti-hair keratin monoclonal antibodies HKN-2, HKN-4, and HKN-6.
- Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia
- Hair Growth-Promoting Effects of a Multi-Targeted Cosmetic Formulation Containing PYGL, DP2, and 15-PGDH Inhibitors Developed Using AI-Based DeepZema® in Androgenetic Alopecia: A 24-Week Randomized Controlled Trial
- 28th Turkish National Dermatology Congress, September 24–28, 2019, Antalya, Turkey
- Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24‐week randomized, double‐blind, placebo‐controlled clinical trial
- Faculty Opinions recommendation of Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial.
- Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968)